


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A compound having a structure set forth in formula (I):



wherein:

- (a) R₄-R₆, and R₈-R₁₀ are hydrogen;
- (b) R₁, R₂, and R₃ are each independently selected from the group consisting of hydrogen, halogen, carboxylic acid, optionally substituted ester, optionally substituted amide, optionally substituted alkyl, optionally substituted alkoxy, trihalomethyl, optionally substituted aryl, and optionally substituted heteroaryl; and
- (c) R₇ is selected from the group consisting of substituted alkyl and substituted alkoxy; or a pharmaceutically acceptable salt thereof.

2. (Original) The compound of claim 1, wherein:

- (a) R₁ is selected from the group consisting of hydrogen and optionally substituted alkyl;
- (b) R₂ and R₃ are each independently selected from the group consisting of hydrogen, halo, carboxylic acid, optionally substituted heteroaryl, and optionally substituted phenyl; and
- (c) R₇ is selected from the group consisting of lower alkyl substituted with a heteroaliphatic ring or dialkylamino and lower alkoxy substituted with a heteroaliphatic ring or dialkylamino.

3. (Original) The compound of claim 2 wherein:

- (a) R₁ is selected from the group consisting of hydrogen;
- (b) R₂ is hydrogen, halo, phenyl, or carboxylic acid; and
- (c) R₃ is hydrogen, halo, carboxylic acid, optionally substituted pyridyl, and phenyl optionally substituted with lower alkoxy or halo; and
- (d) R₇ is lower alkyl substituted with a heteroaliphatic ring or dialkylamino.

4. (Original) The compound of claim 3 wherein R₇ is selected from the group consisting of 3-diethylaminopropyl and 3-pyrrolidin-1-yl-propyl.

5. (Original) The compound of claim 3 wherein:

- (a) R₁ is selected from the group consisting of hydrogen;
- (b) R₂ is hydrogen, halo, phenyl, or carboxylic acid;
- (c) R₃ is hydrogen, halo, carboxylic acid, optionally substituted pyridyl, and phenyl optionally substituted with lower alkoxy or halo; and
- (d) R₇ is lower alkoxy substituted with a heteroaliphatic ring or dialkylamino.

6. (Original) The compound of claim 5, wherein R₇ is selected from the group consisting of 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 2-pyrrolidin-1-yl-ethoxy, and 2-morpholin-4-yl-ethoxy.

7. (Original) A compound selected from the group consisting of:

- 3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,
- 5-bromo-3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,
- 3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-6-phenyl-1,3-dihydro-indol-2-one,
- 3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-5-phenyl-1,3-dihydro-indol-2-one,

3-[5-(2-dimethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-5-phenyl-1,3-dihydro-indol-2-one,

5-phenyl-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one

5-bromo-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-6-phenyl-1,3-dihydro-indol-2-one,

3-[5-(2-dimethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

5-bromo-3-[5-(2-dimethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-dimethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-6-phenyl-1,3-dihydro-indol-2-one,

3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

5-bromo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

6-phenyl-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-diethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

5-bromo-3-[5-(2-diethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-diethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-6-phenyl-1,3-dihydro-indol-2-one,

3-[5-(2-diethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-5-phenyl-1,3-dihydro-indol-2-one,

3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,
5-bromo-3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,
3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-6-phenyl-1,3-dihydro-indol-2-one,
3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-5-phenyl-1,3-dihydro-indol-2-one,
3-[5-(3-pyrrolidin-1-yl-propyl)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,
2-oxo-3-[5-(3-pyrrolidin-1-yl-propyl)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indol-5-carboxylic acid,
2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-carboxylic acid,
2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-6-carboxylic acid,
4-(2-hydroxy-ethyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,
6-pyridin-3-yl-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,
6-(4-methoxy-phenyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,
6-(3-methoxy-phenyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,
6-(2-methoxy-phenyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,
6-(4-fluoro-phenyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-carboxylic acid,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-6-carboxylic acid,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-5-phenyl-1,3-dihydro-indol-2-one,

4-(2-hydroxy-ethyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-6-pyridin-3-yl-1,3-dihydro-indol-2-one,

6-(4-methoxy-phenyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

6-(3-methoxy-phenyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

6-(2-methoxy-phenyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

and 6-(4-fluoro-phenyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one;

or a pharmaceutically acceptable salt thereof.

Claims 8 – 25 (Cancelled).